PharmTech Drug Digest 11.20
News|Videos|November 18, 2026

Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Global Market Competition

Nate Edwards of Arya Consulting, Elisabeth Gardiner of Tevard Biosciences, and Donny Xu of the RTW Institute discuss global competition for rare disease therapies.

In this bonus content from the Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval webcast, Nate Edwards of Arya Consulting, Elisabeth Gardiner of Tevard Biosciences, and Donny Xu of the RTW Institute discuss how the global market is impacting rare disease treatment development.

Despite the growing number of therapies coming out of China, Gardiner stresses that it’s important that safe, effective drugs reach patients than about where they are made, and that competition drives innovation. Her concern is that all developers work within an even framework. She pointed to recent setbacks in investigator-initiated gene therapy trials, warning that a single failure can damage how investors view an entire modality. Speed matters when unmet need is high, she said, but trials must still be run with full rigor and every safeguard in place. She expects new rules adopted since those incidents to reshape the landscape over the next year.

The panel discussed most favored nation (MFN) drug pricing and its effect on commercialization outside the United States. Gardiner stressed that developers need to stay adaptive. She called reimbursement the biggest hurdle of the past decade and argued that access to life-saving medicines should have no borders.

Xu noted that new deals with midsized biotechs are emerging, but said the terms of last year’s Big Pharma agreements remain undisclosed, which makes their impact hard to judge. MFN likely matters less for rare disease drugs than for high-revenue indications such as diabetes and heart failure, according to the panelists. Xu added that where a drug launches first, and how long pricing negotiations take, can delay patient access abroad by a year or more.

Click the video above to watch the segment.

Click here to watch part 1 of the webcast.

Click here to watch part 2 of the webcast.


Related to this article

Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.